Evaluation of the effectiveness of modern treatment approaches for precancerous diseases of the vulva
DOI:
https://doi.org/10.12775/JEHS.2024.58.017Keywords
vulvar intraepithelial neoplasia, vulvectomy, photodynamic therapy, treatment of vulvar intraepithelial neoplasiaAbstract
The aim of the study was to evaluate the effectiveness of modern approaches to the treatment of patients with various types of vulvar intraepithelial neoplasia. Materials and methods. A prospective study of the results of VIN treatment in 262 women aged 25 to 70 years (mean age 51.12±13.41 years) was conducted. Treatment was provided to 155 women with HPV-independent vulvar dysplasia (dVIN), 98 women with severe HPV-independent vulvar dysplasia (VHSIL), and 9 women with grade Ia vulvar Paget's disease. Depending on the type and features of the disease, clinical and morphological characteristics, size, location, age and anamnesis, a particular treatment method was chosen, namely: excision, photodynamic therapy (PDT) with chlorine E6; PDT with 5-aminolevulinic acid; 5% imiquimod cream; vulvectomy (partial/complete). In some cases, a combination of methods was used: excision and 5% imiquimod cream; excision with PDT with 5-aminolevulinic acid. Results. Cream with 5% imiquimod was used in our study mainly in women with VHSIL and showed quite high efficacy in the treatment process. After 3 months, partial regression was registered in 93.75% of cases, after six months, complete regression occurred in 71.87% of patients, and after a year - in 81.25% of women. Morphologically, after 3 months, the recurrence of the disease was registered only in 31.25% of patients, while over time a complete coincidence of clinical and morphological indicators was registered. Combined therapy with imiquimod showed high efficacy both clinically and morphologically with complete regression of the disease (100%) and absence of relapses during the year of follow-up in all patients to whom this approach was used. Treatment with the systemic use of PDT with chlorin E6 showed a complete regression of the pathological focus clinically and morphologically in 96.65% of women after 3 months. The same indicators remained after 6 months, but after a year, the percentage of women with partial regression with morphologically confirmed recurrence slightly increased to 15.08%. Conclusions. Modern methods of conservative treatment of vulvar intraepithelial neoplasia using imiquimod cream and systemic photodynamic therapy can be a highly effective alternative to surgical intervention.
References
Höhn AK, Brambs CE, Hiller GGR, May D, Schmoeckel E, Horn LC. 2020 WHO Classification of Female Genital Tumors. Geburtshilfe Frauenheilkd. 2021 Oct;81(10):1145-1153. doi: 10.1055/a-1545-4279.
van de Nieuwenhof HP, Massuger LF, van der Avoort IA, Bekkers RL, Casparie M, Abma W, et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur J Cancer. 2009 Mar;45(5):851-6. doi: 10.1016/j.ejca.2008.11.037.
Mendivil AA, Abaid L, Epstein HD, Rettenmaier MA, Brown JV 3rd, Micha JP, et al. Paget's disease of the vulva: a clinicopathologic institutional review. Int J Clin Oncol. 2012 Dec;17(6):569-74. doi: 10.1007/s10147-011-0325-0.
Karam A, Dorigo O. Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease. Gynecol Oncol. 2012 May;125(2):346-51. doi: 10.1016/j.ygyno.2012.01.032.
Niikura H, Yoshida H, Ito K, Takano T, Watanabe H, Aiba S, et al. Paget's disease of the vulva: clinicopathologic study of type 1 cases treated at a single institution. Int J Gynecol Cancer. 2006 May-Jun;16(3):1212-5. doi: 10.1111/j.1525-1438.2006.00602.x.
Thuijs NB, van Beurden M, Bruggink AH, Steenbergen RDM, Berkhof J, Bleeker MCG. Vulvar intraepithelial neoplasia: Incidence and long-term risk of vulvar squamous cell carcinoma. Int J Cancer. 2021 Jan 1;148(1):90-98. doi: 10.1002/ijc.33198.
Bodelon C, Madeleine MM, Voigt LF, Weiss NS. Is the incidence of invasive vulvar cancer increasing in the United States? Cancer Causes Control. 2009 Nov;20(9):1779-82. doi: 10.1007/s10552-009-9418-8.
Clifford GM, Georges D, Shiels MS, Engels EA, Albuquerque A, Poynten IM, et al. A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer. 2021 Jan 1;148(1):38-47. doi: 10.1002/ijc.33185.
Preti M, Joura E, Vieira-Baptista P, Van Beurden M, Bevilacqua F, Bleeker MCG, et al. The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD) and the European Federation for Colposcopy (EFC) Consensus Statements on Pre-invasive Vulvar Lesions. J Low Genit Tract Dis. 2022 Jul 1;26(3):229-244. doi: 10.1097/LGT.0000000000000683.
Bigby SM, Eva LJ, Fong KL, Jones RW. The Natural History of Vulvar Intraepithelial Neoplasia, Differentiated Type: Evidence for Progression and Diagnostic Challenges. Int J Gynecol Pathol. 2016 Nov;35(6):574-584. doi: 10.1097/PGP.0000000000000280.
Regauer S. Residual anogenital lichen sclerosus after cancer surgery has a high risk for recurrence: a clinicopathological study of 75 women. Gynecol Oncol. 2011 Nov;123(2):289-94. doi: 10.1016/j.ygyno.2011.07.010.
Satmary W, Holschneider CH, Brunette LL, Natarajan S. Vulvar intraepithelial neoplasia: Risk factors for recurrence. Gynecol Oncol. 2018 Jan;148(1):126-131. doi: 10.1016/j.ygyno.2017.10.029.
de Witte CJ, van de Sande AJ, van Beekhuizen HJ, Koeneman MM, Kruse AJ, Gerestein CG. Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: a review. Gynecol Oncol. 2015 Nov;139(2):377-84. doi: 10.1016/j.ygyno.2015.08.018.
van Seters M, Fons G, van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study. J Reprod Med. 2002 Sep;47(9):701-5.
Mathiesen O, Buus SK, Cramers M. Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study. Gynecol Oncol. 2007 Nov;107(2):219-22. doi: 10.1016/j.ygyno.2007.06.003.
van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, Kagie MJ, Meijer CJ, Aaronson NK, Kleinjan A, Heijmans-Antonissen C, Zijlstra FJ, Burger MP, Helmerhorst TJ. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med. 2008 Apr 3;358(14):1465-73. doi: 10.1056/NEJMoa072685.
Terlou A, van Seters M, Ewing PC, Aaronson NK, Gundy CM, Heijmans-Antonissen C, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. Gynecol Oncol. 2011 Apr;121(1):157-62. doi: 10.1016/j.ygyno.2010.12.340.
van der Linden M, Meeuwis KA, Bulten J, Bosse T, van Poelgeest MI, de Hullu JA. Paget disease of the vulva. Crit Rev Oncol Hematol. 2016 May;101:60-74. doi: 10.1016/j.critrevonc.2016.03.008.
van der Linden M, Meeuwis K, van Hees C, van Dorst E, Bulten J, Bosse T, et al. The Paget Trial: A Multicenter, Observational Cohort Intervention Study for the Clinical Efficacy, Safety, and Immunological Response of Topical 5% Imiquimod Cream for Vulvar Paget Disease. JMIR Res Protoc. 2017 Sep 6;6(9):e178. doi: 10.2196/resprot.7503.
Marchitelli C, Peremateu MS, Sluga MC, Berasategui MT, Lopez DG, Wernicke A, et al.. Treatment of primary vulvar paget disease with 5% imiquimod cream. J Low Genit Tract Dis. 2014 Oct;18(4):347-50. doi: 10.1097/LGT.0000000000000053.
Gentile M, Bianchi P, Sesti F, Sopracordevole F, Biamonti A, Scirpa P, et al. Adjuvant topical treatment with imiquimod 5% after excisional surgery for VIN 2/3. Eur Rev Med Pharmacol Sci. 2014 Oct;18(19):2949-52.
Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, et al. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res. 2001 Jan 1;61(1):192-6.
Zawislak AA, Price JH, Dobbs SP, McClelland HR, McCluggage WG. the management of vulval intraepithelial neoplasia in Northern Ireland. Int J Gynecol Cancer. 2006 Mar-Apr;16(2):780-5. doi: 10.1111/j.1525-1438.2006.00375.x.
Fehr MK, Hornung R, Degen A, Schwarz VA, Fink D, Haller U, Wyss P. Photodynamic therapy of vulvar and vaginal condyloma and intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Lasers Surg Med. 2002;30(4):273-9. doi: 10.1002/lsm.10048.
Hillemanns P, Wang X, Staehle S, Michels W, Dannecker C. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol Oncol. 2006 Feb;100(2):271-5. doi: 10.1016/j.ygyno.2005.08.012.
Campbell SM, Gould DJ, Salter L, Clifford T, Curnow A. Photodynamic therapy using meta-tetrahydroxyphenylchlorin (Foscan) for the treatment of vulval intraepithelial neoplasia. Br J Dermatol. 2004 Nov; 151(5):1076-80. doi: 10.1111/j.1365-2133.2004.06197.x.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 V. Dunaevskaya
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 75
Number of citations: 0